Heterocyclic compounds useful as dual atx/ca inhibitors

Compounds of formula (I)

• wherein
• R1 is selected from
• i) phenyl substituted by R3, R4 and R5,
• ii) pyridinyl substituted by R3, R4 and R5, and
• iii) thiophenyl substituted by R3, R4 and R5;
• X is selected from
• i) N, and
• ii) CH;
• Y is selected from
• i) —CH2—OC(O)—,
• ii) —(CH2)qC(O)—,
• iii) —(CH═CH)r—C(O)—, and
• iv) —(CH≡CH)r—C(O)—;
• W is selected from
• i) —(CR9R10)p—,
• ii) —(CR9R10)p—C(O)—,
• iii) —(CR9R10)p—O—,
• iv) —(CR9R10)—S—,
• v) —(CR9R10)p—S(O)—, and
• vi) —(CR9R10)p—S(O)2—;
• R2 is selected from
• i) substituted phenyl, wherein the phenyl ring is substituted by R6, R7 and R8,
• ii) substituted pyridinyl, wherein the pyridinyl ring is substituted by R6, R7 and R8,
• iii) substituted thiophenyl, wherein the thiophenyl ring is substituted by R6, R7 and R8, and
• iv) substituted thiazolyl, wherein the thiazolyl ring is substituted by R6, R7 and R8;
• R3 is selected from
• i) halo-C1-6-alkoxy,
• ii) C3-8-cycloalkyl,
• iii) C3-8-cycloalkyl-C1-6-alkyl,
• iv) C3-8-cycloalkyl-C1-6-alkoxy,
• v) C3-8-cycloalkoxy,
• vi) C3-8-cycloalkoxy-C1-6-alkyl,
• vii) tetrazolylmethyl,
• viii) triazolylmethyl,
• ix) pyrazolylmethyl,
• x) C1-6-alkyltetrazolylmethyl,
• xi) C1-6-alkyltriazolylmethyl,
• xii) C1-6-alkylpyrazolylmethyl,
• xiii) heterocycloalkyl-C1-6-alkoxy;
• R4 is selected from
• i) halogen,
• ii) hydroxy,
• iii) cyano,
• iv) C1-6-alkyl,
• v) C1-6-alkoxy,
• vi) C1-6-alkoxy-C1-6-alkyl,
• vii) halo-C1-6-alkoxy,
• viii) halo-C1-6-alkyl,
• ix) hydroxy-C1-6-alkyl,
• x) C3-8-cycloalkyl,
• xi) C3-8-cycloalkyl-C1-6-alkyl,
• xii) C3-8-cycloalkyl-C1-6-alkoxy,
• xiii) C3-8-cycloalkoxy,
• xiv) C3-8-cycloalkoxy-C1-6-alkyl,
• xv) C1-6-alkylcarbonylamino,
• xvi) C3-8-cycloalkylcarbonylamino,
• R5 is selected from
• i) H,
• ii) halogen,
• iii) hydroxy,
• iv) cyano,
• v) C1-6-alkyl,
• vi) C1-6-alkoxy,
• vii) C1-6-alkoxy-C1-6-alkyl,
• viii) halo-C1-6-alkoxy,
• ix) halo-C1-6-alkyl,
• x) hydroxy-C1-6-alkyl,
• xi) C3-8-cycloalkyl,
• xii) C3-8-cycloalkyl-C1-6-alkyl,
• xiii) C3-8-cycloalkyl-C1-6-alkoxy,
• xiv) C3-8-cycloalkoxy,
• xv) C3-8-cycloalkoxy-C1-6-alkyl,
• xvi) C1-6-alkylcarbonylamino,
• xvii) C3-8-cycloalkylcarbonylamino,
• R6 is aminosulfonyl;
• R7 and R8 are independently selected from
• i) H,
• ii) halogen,
• iii) hydroxy,
• iv) cyano,
• v) C1-6-alkyl,
• vi) C1-6-alkoxy,
• vii) C1-6-alkoxy-C1-6-alkyl,
• viii) halo-C1-6-alkoxy,
• ix) halo-C1-6-alkyl,
• x) hydroxy-C1-6-alkyl,
• xi) C3-8-cycloalkyl,
• xii) C3-8-cycloalkyl-C1-6-alkyl,
• xiii) C3-8-cycloalkyl-C1-6-alkoxy,
• xiv) C3-8-cycloalkoxy, and
• xv) C3-8-cycloalkoxy-C1-6-alkyl;
• R9 and R10 are independently selected from
• i) H,
• ii) C1-6-alkyl, and
• iii) C3-8-cycloalkyl;
• m and n are independently selected from zero, 1, 2, 3, 4 or 5, with the proviso that the sum of m and n is 2, 3, 4 or 5;
• p is selected from zero, 1 or 2;
• q is selected from zero or 2;
• r is selected from zero and 1;
• or pharmaceutically acceptable salts.